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New approaches oftherapeutic cancervaccinationareneeded toimprovetheantitumoractivity of T cells fromcancerpatients. We
studied over the last years the activation ofhuman T cells for tumor attack. To this end, we combined the personalized therapeutic
tumor vaccine ATV-NDV—which is obtained by isolation, short in vitro culture, irradiation, and infection of patient’s tumor
cells by Newcastle Disease Virus (NDV)—with bispeciﬁc antibodies (bsAbs) binding to this vaccine and introducing anti-CD3
(signal1) andanti-CD28 (signal2) antibody activities. This vaccine called ATV-NDV/bsAb showed the unique abilityto reactivate
a preexisting potentially anergized antitumor memory T cell repertoire. But it also activated naive T cells to have antitumor
properties in vitro and in vivo. This innovative concept of direct activation of cancer patients’ T cells via cognate and noncognate
interactions provides potential for inducing strong antitumor activities aiming at overriding T cell anergy and tumor immune
escape mechanisms.
1.Introduction
For decades, treatment of cancer has focused primarily on
surgery, chemotherapy, and radiation. Despite signiﬁcant
advances by the introduction of new chemotherapeutic
agentsandalsorecentlybytheclinicalintroductionofmono-
clonal antibodies, major limitations of such treatments keep
the inability to eliminate the last tumor cell. The oﬀspring
of those tumor cells that were not destroyed by the ﬁrst-line
treatment may have a selective advantage, leaving the patient
witharecurrenceofcancerthatisoftenwidespreadandresis-
tant to further chemotherapy or radiotherapy. Therefore,
more eﬀective therapies are needed. Immunotherapy based
on antitumor immune memory is a new modality for cancer
treatment. It holds great promise for aﬀecting in a positive
way cancer patients’ survival with minimal toxicity.
For over 200 years, active immunotherapy approaches
have been used to successfully prevent numerous infectious
diseases such as smallpox. These active immunotherapy
concepts are now being applied to develop therapeutic
cancer vaccines with the intention of treating existing
tumors and/or preventing tumor recurrence. In principle,
anticancer vaccination (e.g., with autologous tumor cells,
peptide vaccines, dendritic cells, idiotypic antibodies, and
virus-based vaccines) is a meaningful additional approach
for treatment of cancer [1].
Tumor antigens (TAs) of patients’ tumor cannot be
recognized directly by the patients’ T cells. They need ﬁrst
to be processed and to be properly presented by specialized
cells that are known as professional antigen-presenting cells
(APCs) such as dendritic cells (DCs). TA-presenting DCs
then migrate to lymph nodes, where they induce immunity
in TA-speciﬁc naive T cells. This results in the diﬀerentiation
into eﬀector T cells—mainly CD8+ cytolytic T cells (CTLs),
which are capable of destroying tumor cells expressing the
tumor antigen. The response also leads to the generation2 Clinical and Developmental Immunology
of TA-speciﬁc memory T cells which provide immune
protection against tumor recurrence.
Despite promising results of cancer vaccination obtained
in animal tumor models, results of published vaccine trials
reveal only a weak clinical response rate with less than 1%
for active speciﬁc immunization procedures in colorectal
cancer patients [2]. At the Surgery Branch of the National
Cancer Institute (Bethesda, Maryland, USA), an objective
response rate of only 2.6% was reported [3] with various
cancer vaccines, even though about 50% of the vaccinated
patients had developed CTL killer cells able to speciﬁcally
recognize and kill tumor cells in vitro.
Diﬃculties met by vaccination approaches to cancer
treatment have been attributed to tumor immune avoidance
mechanisms [4]. Tumors employ many escape strategies
in order to evade immune attack. These strategies include
downregulation of MHC molecules in order to hide from
immunerecognition [5],expression ofinhibitory factorsand
immunosuppressive cytokines [6–8], including TGF-β [9,
10], IL-10 [11], and recruitment of regulatory immune cells
CD4+CD25+FoxP3+ Tregs [12], Tr1 cells [13], tolerogenic
DCs, and myeloid suppressor cells, including immature
macrophages, granulocytes, DCs, and other myeloid cells
at earlier stages of diﬀerentiation [14, 15]. These immune
avoidance mechanisms employed by tumors render the
immune system tolerant. This may be responsible for tumor
immune evasion as many of the tolerance mechanisms that
prevent autoimmunity are the same as employed by tumors
to prevent immune destruction [16, 17].
In order to develop an eﬀective immunotherapy strategy
for metastatic cancer, new approaches are required that not
only can create and enhance tumor-speciﬁc immunity but
canalso counteracttheabilityof thetumor toevadeimmune
destruction.To thisend,T cells ofthecancerpatientsneed to
beeducatedto attacktumorcells. NaiveCD8+Tcellsrequire
two distinct signals for activation: signal 1 is provided by
engagement of the TCR with its cognate ligand, and signal
2 is provided by interaction of costimulatory receptors with
theirrespective ligands ontheAPCs[18, 19].Memory CD8+
T cells, which have been primed to TA, are often anergic and
need to be properly reactivated in order to be able to destroy
the tumor cells.
T h ed e s i g no fa ne ﬃcient antitumor vaccine may be
inﬂuenced by an important paradigm shift in the ﬁeld of
immunology regarding the regulation of immunity. A new
concept has emerged that proposes that the regulation of
immunity and tolerance is not only determined by the
speciﬁcity of immune T cells as previously thought but
also by the context in which the antigens are presented
to the immune system [20, 21]. The implications are that,
in the absence of appropriate inﬂammatory reactions, the
self- (tumor) antigens presented by APCs will not lead
to T cell activation. Since tumors can also produce anti-
inﬂammatory cytokines, they are capable of inﬂuencing the
immune response by preventing an inﬂammatory response.
Therefore, successful antitumor immunity will develop
only in situations where DCs are processing TAs in the
presence of an inﬂammatory microenvironment (“danger
signals”) which is potent enough to also downregulate
tumor-mediated immunosuppressive cytokine production.
The magnitude and duration of the immune response
will be dependent on the extent and quality of the local
inﬂammatory response and will be contained by a variety of
existing tolerogenic mechanisms.
Previous attempts at developing therapeutic cancer vac-
cines have demonstrated that it is possible to elicit speciﬁc
immunity against self-tumor antigens [2, 3]. Recent insights
on how immunity and tolerance are regulated indicate that
t h ef a i l u r eo ft h e s ev a c c i n e si nt h ec l i n i cm a yb er e l a t e dt ot h e
absence of suﬃcient danger and T cell costimulation signals
at the time when tumor antigens are processed by DCs.
In this paper, we highlight some in vitro and in vivo
observations made during the evaluation of a tumor vaccine
that we developed in our laboratory. The tumor vaccine of
the second generation, modiﬁed with bsAb, will be shown
to be capable to reactivate memory T cells and to activate
nonspeciﬁcally naive T cells against the tumor.
2.The AutologousNDV-Based TumorVaccine
Over the last 10 years, we have developed and evaluated
an autologous tumor vaccine which is ﬁrst modiﬁed by
virus infection and which later was modiﬁed further by
attachment of bispeciﬁc antibodies (see Figure 1). The aim
was to activate with such a vaccine potentially anergized
TA-speciﬁc memory T cells and to activate in addition
nonspeciﬁcally naive T cells to overcome tumor escape
variants that may lack TA expression. For virus infection,
we chose the avian paramyxovirus Newcastle Disease Virus
(NDV) [22]. NDV is one of ﬁve species of viruses that
are under clinical evaluation [23]. It is a negative strand
RNA virus with interesting antineoplastic and immune-
stimulating properties [23, 24]. Most remarkable is its
capacity to induce strong type I interferon responses by viral
protein [24]a n dR N A[ 25]. Detection of foreign RNA in
the cytoplasm by RIG-I induces an innate antiviral program
that initiates the transcription of RNA-responsive genes.
The responses involve a multimodal machinery of gene
regulation by the Interferon Regulatory Factor (IRF) family
of transcription factors [26] and link innate and adaptive
immunity [27]. There are 2 generations of NDV-based
tumor vaccine: the ATV-NDV and ATV-NDV/bsAb.
2.1. First-Generation Vaccine: ATV-NDV. The virus-mod-
iﬁed tumour vaccine developed by us for human applica-
tion consists of virus-infected intact viable and irradiated
autologous tumor cells (see Figure 1). The tumor cell
infection by NDV is designed to provide the necessary
danger signals to elicit antitumor immunity. This strategy is
based on preclinical studies in metastatic animal tumours.
Antimetastatic eﬀectswere observedafterlocal postoperative
vaccination with NDV-infected autologous tumour cells
[28]. The vaccination activated a tumour-line speciﬁc T cell-
mediated immune response, which also protected against a
second challenge with the same tumour line [29].
Tumor cell infection by NDV was found also in
humans to be an eﬃcient and safe way to produce an
autologous tumor vaccine (ﬁrst-generation ATV-NDV) withClinical and Developmental Immunology 3
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Figure 1: Principles of the NDV-based tumor vaccine of the ﬁrst and second generation and status of the art (for more details, see the main
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pleiotropic immuno-stimulatory properties [30]. Promising
results based on the prolongation of survival among cancer
patients with various tumor entities have already been
reported from several clinical phase II trials, including breast
cancer [31, 32], colon carcinoma [33, 34], Head and Neck
SquamousCell Carcinoma(HNSCC)[35], and glioblastoma
[36]. The antitumor clinical eﬃcacy has been shown also
in a randomized study performed among colon carcinoma
patients operated for liver metastasis [37].
2.2. Second-Generation Vaccine: ATV-NDV/bsAb. The use
of NDV during the generation of the ATV-NDV tumor
vaccine presents the advantage that, upon infection, the viral
hemagglutinin-neuraminidase (HN) protein is expressed on
the vaccine cells and can serve as universal anchor molecule
for the binding of new ligand proteins. The ATV-NDV can
then be combined easily with bispeciﬁc antibodies (bsAbs)
binding to the HN protein for introducing anti-CD3 and
anti-CD28 antibodies at the surface of the tumor vaccine
to obtain the NDV-based tumor vaccine of the second
generation (see Figure 1). This novel strategy is designed to
intensify T cellactivation via agonisticanti-CD3 and/or anti-
CD28 single-chain antibody reagents (scFv). When subop-
timal amounts of anti-CD3 are employed, the combination
of TA, anti-CD3, and anti-CD28 should help to intensify
TA-induced signal 1 and HN-induced costimulatory signal
2[ 38, 39]. Because of virus infection, the ATV-NDV/bsAb
vaccine provides a highly inﬂammatory environment for T
cells in the presence of tumor cells. The presence of cell
surface bsAbs binding to CD3 and CD28 receptor molecules
serves among other eﬀects for augmenting signal strength in
T cells to override anergic states of TA-speciﬁc T cells. Signal
intensity and duration (strength) of TCR stimulation has an
impact on setting the balance between adaptive responses
and immunopathology [40] and inﬂuences induction of T
cell activation or anergy [41]. Signal strength, timing, and
tuning are also important for T cell costimulation (signal
2). Combining optimal signals 1 and 2 at the surface of
the tumor vaccine is expected to generate strong antitumor
adults. We showed over the last years that this vaccine acts
on TA-speciﬁc memory T cells but also on naive T cells via
TA-dependent and TA-indepentent pathways.
3.Reactivation of TA-Speciﬁc Memory T Cells
fromCancerPatientsuponOptimal
Combination of bsHN-CD3 and bsHN-CD28
withtheVaccineATV-NDV
The ATV-NDV tumor vaccine of the second generation
was capable of reactivating anergic T cells from tumor-
draining lymph nodes of cancer patients. This was revealed4 Clinical and Developmental Immunology
via a modiﬁed short-term IFN-γ ELISpot assay which we
established for reactivation of cancer-reactive memory T
cells. As shown in Figure 2(A), from four diﬀerent head and
neck squamous cell carcinoma (HNSCC) patients, primary
tumor cells were expanded in vitro, and, from each tumor
line, autologous tumor vaccines were prepared as a vaccine
(through irradiation, infection by NDV, and loading with
the bsAbs). These vaccines were ﬁnally combined with T
cells isolated from tumor-draining lymph nodes from the
corresponding HNSCC patients. The data from Figure 2(B)
show a strong IFN-γ response only in that group where
T cells were stimulated with autologous TAs together with
anti-CD3 and anti-CD28 signals. These responses required
HNSCC-derived TAs. Another tumor line (the heterologous
promonocytic U937 cell line) modiﬁed following the same
waycouldnotreactivateashort-termmemoryresponsefrom
the patients’ T cells (Figure 2 (B), lower part).
We conclude
(i) that tumor-reactive memory T cells from draining
lymph nodes of HNSCC patients could not be
activatedwiththeﬁrst-generationvaccineATV-NDV,
(ii) that the cells, however, could become eﬃciently
reactivated using the same vaccine together with
optimized signals 1 and 2, and
(iii) that a similarly modiﬁed vaccine from an unrelated
tumor cell line was not capable to elicit such a
memory T cell response.
The fact that the ATV-NDV vaccine without bsAbs was
not capable to reactivate a response might be explained by
an anergic state of the tumor-draining lymph node-derived
T cells.
4.ActivationofAntitumorActivityfromNaiveT
Cellsby theSecond-GenerationVaccine
The tumor vaccine ATV-NDV/bsAb was shown to have
also an eﬀect on naive T cells which were obtained from
total T cells of normal healthy donors by removal of
the CD45RO+ cells. This was observed by analyzing the
activation of thenaive T cellstowards tumorcellsafter 6days
ofincubationwithvariousvaccines.Figure 3(A)showsCD25
and CD45RO expression on naive T cells upon coincubation
with various NDV-based tumor vaccines. 1 × 105 naive T
cells from a normal healthy donor were labeled with CFSE.
They were then coincubated with 1 × 104 irradiated MCF-
7 cells which were modiﬁed with 100 HU NDV Ulster and
with suboptimal bsHN-CD3 (500pg/well) and 84.4U/well
bsHN-CD28 (d). Naive T cells, which came in contact only
with the vaccine (a) or with the vaccine loaded with each of
the constructs separately (b and c) served as controls. After
six days, the cells were harvested, blocked with Endobulin,
and then stained with anti-CD25-APC (a) or anti-CD45RO-
PE (b) before being analyzed on the FACS. Dead cells
were excluded by propidium iodide staining. The red boxes
indicate actively dividing (CFSE low) cells expressing CD25
or CD45RO. The frequencies are indicated as numbers in %
(adapted from [42]). We observed a strong activation only
when bothbsAbs(bsHN-CD3and bsHN-CD28)were added
to the tumor vaccine (see Figure 3(A), (d)). Figure 3(B)
shows that tumor growth inhibition induced in naive T cells
uponcoincubationwith variousNDV-basedtumorvaccines.
In order to test the eﬀectiveness of the new vaccine strategy
to activate in vitro naive T cells, an in vitro assay that we
called tumor neutralization assay (TNA) was developed. It
consists of an adherent tumor cell monolayer (here human
MCF-7 breast cancer cells) in a cell culture plate in which
γ-irradiated NDV-modiﬁed vaccine cells, fusion proteins,
and naive T cells of a healthy donor as eﬀector cells are
brought into contact.During the incubation period of ﬁve to
seven days, the vaccine cells activate the eﬀector cells which
increase their cytotoxic potential. During the eﬀector phase,
the “bystander” tumor cells are lysed, or their growth is
inhibited. This results in a decrease in the number of live
tumor cells in monolayer (when compared to the controls).
After removal of the nonadhering remaining eﬀector cells,
the number of surviving tumor cells can be quantiﬁed with
MTS as dye reagent for measuring the amount of viable
tumor cells per well. We observed that the tumor vaccine
with the 2 bound bsAbs bsHN-CD3 and bsHN-CD28was by
farthemosteﬃcientinthisassayamongallthecombinations
of tumor vaccine and bsAbs tested (Figure 3(B)). We also
observed that the extent of T cell-mediated tumor growth
inhibitioninvitrodependedonanoptimalamountofbsHN-
C D 3a n db s H N - C D 2 8p r e s e n ta tt h es u r f a c eo ft h et u m o r
vaccine (data not shown, see [42]). Titration curves revealed
for each of the recombinant proteins, upon attachment to
the vaccine, a low dose optimum, of T cell stimulating or
costimulating activity [42].
A ni m p o r t a n ta s p e c to fTc e l le ﬀector activity relates to
its duration. To test this, we activated puriﬁed T cells once
by coculture with the second-generation vaccine, performed
the TNA, and then repeatedly transferred the T cells from
the suspension above the destroyed monolayer onto fresh
tumor monolayers and followed their destruction thereafter.
In these ways, live adherent MCF-7 monolayers were coin-
cubated in 96-well plates with MCF-7-NDV vaccine cells,
puriﬁed T cells, a suboptimal dose of bsHN-CD3 (1μg
per 107 vaccine cells; signal 1), and one of the following
costimulatory fusion proteins: bsHN-CD28 (signal 2a) or
tsHN-IL-2-CD28 (signal 2a-2b), each at a concentration
of 84U per 107 vaccine cells (passage 0). T cells activated
in the presence of suboptimal bsHNCD3 alone (negative
controls) showed no tumor growth inhibition in this assay
(data not shown). For serial passages, the same conditions
were performed in parallel using a 6-well TNA format with
identical protein concentrations (TNA passage plates). After
7 days, the TNA test plates were developed using MTS as
reagent to obtain the value of tumor growth inhibition as
described in [43]. The cells from the TNA passage plates
were harvested, washed, and transferred for another 3 days
onto fresh MCF-7 monolayers, either in 96-well TNA test
plates(passage 1) orin6-well TNApassage platesforanother
round (passage 2). The results (Figure 3(C))revealedamuch
longer duration of bystander antitumor activity in T cells
activated by the vaccine bound bsHN-CD3 and bsHN-CD28
(group b) than in T cells activated by the vaccine aloneClinical and Developmental Immunology 5
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Figure 2: Reactivation of tumor-reactive memory T cells of cancer patients (here HNO cancer patients) by the ATV-NDV tumor vaccine
of the 2nd generation. (A) Protocol for the ex vivo stimulation of T cells from cancer patients by the NDV-based tumor vaccine of the
second generation in an autologous setting. Puriﬁed T cells isolated from tumor-draining lymph nodes (LN) of HNSCC patients were
tested for their capacity to be restimulated and to produce IFN-γ upon contact with various combination of the ATV-NDV tumor vaccine
(generated from the autologous tumor) and bsAbs molecules. For that, they were coincubated for 40 hours with the indicated autologous
vaccineformulations(tumor)(n = 4).Forspeciﬁcity control,theunrelated humanpromonocytictumorcell lineU937(U937)wasmodiﬁed
identically and used to reactivate the patients’ T cells. (B) IFN-γ ELISPOT results from A. Mean: mean number from triplicates of 4 patients
spot forming T cells per 1 million cells. Each patient’s T cells were stimulated with four diﬀerent formulationsof either autologous (a–d) or
heterologous (e–h) vaccine.T cells ofpatientsno.2,no.3,andno.4alsodidnotreact to the heterologous vaccine(data notshown)(adapted
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Figure 3: Activation of naive T cells towards tumor cells by the NDV-based tumor vaccine combined with bsAbs in diﬀerent combinations.
(groupa).Wehaveconstructedalsoatrispeciﬁc recombinant
fusion protein (tsHN-IL-2-CD28) in which the cytokine
interleukin-2 was linked in between the anti-HN and the
anti-CD28 scFv binding sites [42]. Since we had observed
that vaccine-bound IL-2 can deliver costimulatory signal
via CD25 (the IL-2 receptor alpha chain) to T cells, we
were then interested to test whether the combination of
costimulatory signals delivered via anti-CD28 and via IL-2
might have an advantage. As can be seen from the results in
Figure 3(C), group c, this type of modiﬁed vaccine induced
antitumor eﬀecteractivity ofthe longest duration. Expressed
quantitatively, a simultaneous introduction of costimulatoryClinical and Developmental Immunology 7
signals via CD28 (signal 2a) and IL-2 receptor (signal 2b)
led to a 20–40% increased bystander antitumor activity in
passage 1 (days 7–10) and passage 2 (days 10–13) when
compared to a tumor vaccine with only one costimulatory
signal (for more details, see [42]).
5. Human PBMC PreactivatedIn Vitroby
the NDV-Based TumorVaccine of
the SecondGenerationShowsInVivo
TherapeuticEfﬁciencyuponAdoptive
Transfer to Tumor-Bearing Mice
To study possible immunotherapeutic eﬀects of vaccine-
activated PBMC in vivo, we used a NOD/SCIDmouse model
which allows outgrowth of human MCF-7 breast cancer
cells [44]. For therapy, PBMCs from a healthy donor were
preactivated with an MCF-7-NDV tumor vaccine loaded or
not withbsHN-CD3and bsHN-CD28[42].The preactivated
cells were then transferred via intraperitoneal injections into
mice with established MCF-7 xenotransplants (Figure 4(A)).
PBS-treated control mice showed progressive tumor growth,
as did tumors from mice treated with PBMC preactivated
with MCF-7-NDV tumor vaccine. The tumors of mice,
however, treated with PBMCs, which were preactivated with
the NDV-based tumor vaccine of the second generation,
started to regress 51 days after adoptive cell transfer and
showed at day 93 much smaller tumor diameters when
compared to tumors of mice treated with the NDV-based
tumor vaccine of the ﬁrst generation (i.e., without the 2
bsAbs) (see Figure 4(B)). Notably, treatment of mice with
supernatants from PBMC cultures preactivated with the
NDV-based tumor vaccine of the second generation did
not lead to tumor regression [42]. Immunohistochemical
stainings of tumors that underwent regression revealed a
heavy inﬁltration by both human CD4+ and CD8+ T cells
(Figure 4(B)), a certain percentage of which were in an
activated state (CD69 positive) and exhibited a memory
phenotype (CD45RO positive) [42]. In contrast, tumor
sections from mice treated with PBMC preactivated with the
MCF-7-NDV tumor vaccine (Figure 4(B)) or with PBS (data
not shown) revealed no tumor-inﬁltrating T cells [42].
In summary, human naive T cells upon stimulation with
the second-generation tumor vaccine and upon transfer in
vivocan—after a certain lag period—inﬁltrate human tumor
tissue and mediate tumor regression.
6.Conclusionand Perspectives
The main question we address in this paper: how can we
exploit maximal antitumor activity from T cells of cancer
patients through antitumor vaccination?
Over the last decades, many types of vaccines have been
developed towards this goal, including synthetic peptides,
“naked” DNA, dendritic cells, or recombinant viruses. Our
approach is based on the use of patient-derived tumor cells
which are irradiated, modiﬁed by infection with NDV, and
coupledwith bispeciﬁcAbsinordertointroducenewligands
for T cell activation at the surface of the tumor vaccine.
We observed that the NDV-based autologous tumor
vaccine of the second generationcan be used for reactivation
of apparently anergic memory T cells from tumor-draining
lymph nodes of individual cancer patients. The danger and
costimulatory signals introduced to the vaccine through
virus infection as well as additional signal 1 and 2 at the
surface of the tumor vaccine appear necessary in cancer
patients whose T cells exhibit a high degree of unrespon-
siveness to stimulation to TA. The underlying mechanism
explaining such antitumor activity is suggested to rely on
direct presentation of autologous TAs (cognate interactions
with memory T cells (see Figure 5)) and on augmentation of
signal intensity by bsAbs.
Theabsenceofanyresponseintheshort-time Interferon-
γ Elispot (see Figure 2, lower part) during the coincubation
of patient T cells and heterologous bsAb-modiﬁed tumor
cells might be explained by the absence of autologous TA.
What is also interesting is the capacity of the NDV-based
tumor vaccine of the 2nd generation to induce antitumor
activity in naive T cells. Such activation of naive T cells
requires, however, a longer time period than that of memory
T cells. The proposed mechanism is direct T cell activation
via noncognate interactions with the vaccine/bsAb leading
to induction of strong bystander antitumor activity (see
Figure 5 and Table 1). These latter observations suggest that
T cells can be activated to exert antitumor activity by such a
newtumorvaccineinaTA-andMHC-independentpathway,
similar to cells of the innate immune system. This new
mechanism may become an important safeguard against
tumor immune escape.
The cells of the adaptive immune system utilize somati-
cally rearranged receptors to recognize antigens. By contrast,
cells of the innate immune system primarily use germline-
encoded receptors to defend against infected or transformed
cells. Interestingly, cells of the adaptive immune system
can express also some of these germline-encoded receptors
[45].
Can T cells, in similarity to cells of the innate immune
system, sense danger? The ﬁrst published “danger model” of
immunity [46] proposed only one mechanism for immune
recognition of danger that perceived by DCs upon release
of cellular contents following necrosis of a diseased cell in
its neighbourhood. This model predicts a superior eﬀect of
a lytic as opposed to a nonlytic virus in the treatment of
tumors, because tumor cells necrotically destroyed by the
virus would be phagocytosed and perceived as dangerous by
DCs. The DCs would (i) process TAs, (ii) become activated,
and (iii) present processed TA peptides to T cells for cognate
interaction and immune response induction.
Another recent model [47] suggests that T lymphocytes
themselves correlate danger signals to antigen. This hypoth-
esis associates danger also with nonlytic viruses (as NDV
Ulster) if these are upregulating danger signals in their host
cells. Such an event will quickly cause its host cells to be
killed by the immune system. Killed infected tumor cells
are likely to result in TA being presented by DC along with
potent costimulation. Recently, it was shown that dsRNA in
theapoptoticbodiesofvirus-infected deadcellsisrecognized
by CD8 alpha+ DCs that have high expression of toll-like8 Clinical and Developmental Immunology
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Figure 4: In vivo antitumor activities of human PBMC preactivated in vitro by the NDV-based tumor vaccine of the second generation. (A)
Experimental protocol. MCF-7 tumor cells were injected subcutaneously into NOD/SCID mice (n = 8 per group). The mice were kept until
palpable tumors were established (6–8mm in diameter) (a). Then, at days 1, 4, and 7, the mice were treated by i.p. injection of 107 PBMC
which were preactivated ex vivo for 3 days by the NDV-based tumor vaccine of the ﬁrst or second generation obtained using the MCF-7 cell
line (b). Tumor growth was then monitored over time (c). (B) Tumor diameter and representative immunohistochemistry images of tumor
tissue sections. Tumor-bearing mice were treated with PBMC activated with MCF7-NDV (left) or with PBMC preactivated with MCF-7-
N D Vl o a d e dw i t hb s H N - C D 3a n db s H N - C D 2 8( r i g h t )a n dw e r ea n a l y z e do v e rt i m ef o rt u m o rg r o w t h ,a n dd a t aa td a y9 3i sr e p r e s e n t e d
(top). At this time point, some mice were sacriﬁced, and the tumor sections were stained with mAbs against the human CD8 antigen and
analyzed by ﬂuorescence microscopy (bottom). Scale bar, 100μm (adapted from [42]).
receptor 3 (TLR-3) [48]. This promotes cross-priming of T
cells to virus-infected cells [49].
Recent data support a role for CD8+ T cells in
innate immune responses, independent of TCR speciﬁcity.
Under certain circumstances, antigen non-speciﬁc TCR-
independent responses of CD8+ T cells play a beneﬁcial role
in controlling tumors [50]. Marsland et al. [51] showed that
innate signals driven by DC can compensate for the absence
of PKC-Φ, which is important for TCR signalling, during
CD8+ T cell eﬀector and memory responses in vivo.
The discovery of toll-like receptors (TLRs) and more
recently of cytosolic innate immune sensors such asClinical and Developmental Immunology 9
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Figure 5: Cognate and noncognate antitumor mechanisms induced by the NDV-based tumor vaccine of the second generation (ATV-
NDV/bsAbs). The diﬀerent mechanisms of T cell activation against tumor suggested explaining the eﬃcacy of the ATV-NDV/bsAb in
inducing antitumor activity in T cells are highlighted. (a) Direct antigen presentation of TA to memory T cells. Addition of danger signals
via NDV infection of the tumor cells during the elaboration of the tumor vaccine induces a reactivation of the antitumor reactivity in TA-
speciﬁc memory T cells [32]. This mechanism is intensiﬁed by the addition of the 2 bsAbs introducing binding activities to CD3 and CD28
at the surface of the tumor vaccine (see Figure 2). + signal intensiﬁcation via bsAb (memory T cells). (b) Cross-presentation via DCs in vivo
(naive T cells). (c) Direct polyclonal activation this pathway is highlighted in this manuscript.
Table 1:Summaryofthetypesofinteractions,mechanisms,characteristicsoftheimmuneresponsesinducedbytheATV-NDV/bsAbvaccine
in memory and naive T cells and the eventual danger of autoimmunity (see the main text for more details).
Vaccine + bsAbs Interactions
T cells-tumor cells Mechanisms Response characteristics Autoimmunity
T A+b s C D 3+b s C D 2 8 C o g n a t e
Restimulation (memory)/TA
cross-presentation via DCs (naive)
⇒ TA-speciﬁc T cell activation
Long-term eﬀect
systemic Low risk
bsCD3 + bsCD28 Noncognate
Provision of inﬂammatory and
danger signals ⇒ Non-TA-speciﬁc T
cell activation
Transient, local High risk
RIG-I-like receptors (RLRs) and nod-like receptors (NLRs)
as components that recognize structures of “danger” such as
pathogenshas greatlyadvanced understanding ofhow innate
immune response can be triggered and can prime antigen-
speciﬁc adaptive immunity. Cytotoxic CD8+ T cells and T
helper1(Th1)cellsare centraltoeﬀectiveimmune responses
against tumor. However, clinical trials with cancer vaccines
have shown the weakness of responses observed among the
treated cancer patients, although cytotoxic activities speciﬁc
for the targeted TA were detected in vivo [3].
A key determinant in the induction of a strong and
eﬃcient cellular immune response against tumors seems to
be, in addition to a broad repertoire of TA presented by the
tumor cells used as vaccine, the recognition of the TA as
“nonself.” SuchTAshavebeentermed“unique”(individually
tumor speciﬁc) and have a potential to serve as tumor
rejection antigen. The superiority of autologous tumor
vaccines among tumor vaccines evaluated in randomized
clinical studies [52] suggests that unique tumor antigens
are indeed particularly important in generating responsive
T cells for a therapeutic eﬀect. Restimulation of TA-speciﬁc
memory T cells and activation of naive T cells may explain
the strong antitumor potential of the NDV-based and bsAb-
modiﬁed tumor vaccine.10 Clinical and Developmental Immunology
CD8+ T cells have been implicated not only in antigen-
dependent but also in antigen-independent antitumor
responses. Self-reactive CD8+ T cells expressing high levels
of NKG2D induce killing of target cells using a redirected
lysis assay [53]. Furthermore, activation of CD44hi CD8+ T
cellsusingIL-2resultedinsigniﬁcantlyhigherlevelsofkilling
of a syngeneic target compared with CD44loCD8+ T cells
[54]. Expression of the NKG2D ligand Rae-1δ resulted in
increased killing of the syngeneic targets. As the expression
of Rae-1δ is associated with tumors, it seems plausible
that a subset of innate CD8+ T cells activated with IL-2
could directly lyse tumors using NKG2D, independent of
TCR speciﬁcity. Another report characterized CD8+ T cells
in cancer patients receiving IL-12, showing that a subset
of CD8+ T cells expanded and displayed enhanced MHC
nonrestricted cytotoxicity in vitro [55]. This suggests that
cytokinescanstimulatesubsetsofCD8+Tcells,independent
of TCR signalling, to lyse tumors. In this context, it is
interesting to see an example of clinical application: the
transfusion of intentionally mismatched donor lymphocytes
in high-risk chemotherapy-resistant patients with metastatic
solid tumors and haematological malignancies [56].
Danger signals and T cell costimulation have great
therapeutic potential but need to be optimized and con-
trolled. Unfortunately, these same types of innate antigen-
independent responses might be harmful when they are self-
reactive.Therisk factorforinductionofautoimmunedisease
(see Table 1) has been discussed in more detail in a recent
editorial [57].
In summary, the tumor vaccine ATV-NDV/bsAb shows
dual activity: (i) it can activate TA-speciﬁc memory T cells
fromcancerpatients,and(ii)itcangenerateantitumoractiv-
ity from naive T cells. A strategy harnessing both arms of the
immunesystem—innate (basedon noncognateinteractions)
and adaptive (relying on cognate interactions)—holds great
potential for clinical applications in cancer patients.
Our ﬁndings open new ways of investigations to manip-
ulate T cell activity against tumor cells and to exploit the
full power of the immune system through reactivation of
tumor antigen-speciﬁc memory T cells and through de novo
activation of naive T cells. These could, for example, be
based on the combination of new recombinant immunos-
timulatory molecules such as bi- or trispeciﬁc antibodies or
immunocytokines with vaccines which have already proven
clinical eﬀectivity.
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